We are a preclinical neurobiology company leading the discovery and development of small molecule drugs targeting G-protein-coupled receptors (GPCRs) for treating a range of neuropsychiatric and mental health conditions.
Our mission is to bring to patients safe and convenient pharmaceutical options that will provide long lasting benefits beyond what current standards of treatment can offer.
We are leveraging recent advances in the field of molecular biology, biochemistry, and functional brain imaging to address the root causes of the historically high failure rate of clinical trials of neuropsychiatric drugs in the pursuit of a new class of medicines.
OUR PATH FORWARD
By using established biomarkers to measure target engagement in the brain and functional changes in relevant neural circuitry, we are following a rigorous strategy to achieve early clinical proof of mechanism and de-risk later stages of drug development.
Novel, potent, signal-biased, 5-HT2A receptor agonists have shown therapeutic potential in animal models of depression and lack of hallucinogenic-like behavior. High selectivity for the 5-HT2A receptor avoids known cardiac liability mediated by other receptors in this family and potentially allows for chronic use in patients.
We anticipate advancing multiple drug candidates into clinical testing as early as 2024.